RICERCA ITALIANA     

FIRB simili:

• 1 - PROFILO GENOMICO DEI DISORDINI LINFOPROLIFERATIVI ACUTI E CRONICI DELL'UOMO PER LO SVILUPPO DI NUOVE PROPOSTE CLASSIFICATIVE, MARCATORI DI PROGNOSI E STRATEGIE TERAPEUTICHE INNOVATIVE.
• 2 - Progettazione, sintesi e valutazione dell'attività antivirale di inibitori indirizzati su bersagli diversi del ciclo di moltiplicazione dei Flaviviridae.
• 3 - IDENTIFICAZIONE DI DETERMINANTI GENETICI DI SUSCETTIBILITA' IN MALATTIE MULTIFATTORIALI NELLA POPOLAZIONE ITALIANA
• 4 - Identificazione ed analisi funzionale delle alterazioni molecolari e geniche che caratterizzano i tumori della mammella ormono-responsivi

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • PATOLOGIA GENERALE
  • MALATTIE INFETTIVE

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Lombardia

Bibliografia

WP 1-2:
1. Simmonds P.The origin and evolution of hepatitis viruses in humans.J Gen Virol 2001;82:693-712.
2. Pontisso P, et al. Distribution of three major hepatitis C virus genotypes in Italy. A multicentre study of 495 patients with chronic hepatitis C. J Viral Hep 1995;2:33-38.
3. Alberti A,et al. Natural history of hepatitis C. J Hepatol 1999;31 (S1):17-24.
4. Silini E, et al. Differential distribution of hepatitis c virus genotypes in patients with and without liver function abnormalities. Hepatology 1995;21:285-290.
5. Nousbaum JB, et al. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995;127:161-168.
6. Prati D, et al. Sustained response to interferon-alpha2a monotherapy of young blood donors with minimal-to-mild chronic hepatitis C. J Viral Hep 2000;7:352-360.
7. Mondelli MU, et al. Clinical significance of hepatitis C virus genotypes. J Hepatol 1999;31(S1):65-70.
8. Rumi MG, et al. Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough. J Viral Hep 2001; in press.
9. Rumi MG, et al. Serum pattern of aminotransferases in patients with chronic hepatitis C. J Hepatol 2001;34 (S1): Abs 1105.
10. Poynard T, et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832.
11. McHutchinson JG, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med
12. Pietschmann T., et al. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol 2001; 75: 1252-1264.
13. Lohmann V., et al. Mutation in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001; 75:1437-1449.
14. Krieger N., et al. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 2001; 75: 4614-4624.
15. R. Cinelli, et al. The enhanced green fluorescent protein as a tool for the analysis of protein dynamics and localization: local fluorescence study at the single-molecule level, Photochem. and Photobiol. 71, 771 (2000).
16. A. Marcello, et al.Visualization of in vivo direct interaction between HIV-1 TAT and human cyclin T1 in specific subcellular compartments by fluorescence resonance energy transfer. J. Biol. Chem. In press.

WP1-3:
1. Lander ES, et al. (1994) Genetic dissection of complex traits. New Engl J Med, 265:2037-2048.
2. Perera P.P. (1997) Environment and cancer: who are susceptible? Science 278: 1068-1073.
3. Smith C.A.D., et al. (1994). Genetic polymorphisms in xenobiotic metabolism. Eur.J.Cancer 30A(13): 1935-1941.
4. Nebert D.W. (1997). Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am.J.Hum.Genet. 60: 265-271.
5. Vineis P, et al. (1999) Metabolic polymorphisms and susceptibility to cancer. IARC Scientific Publications. Vol. 148. Lion, France: International Agency for Research on Cancer.
6. Farber J.L. (1994) Mechanisms of cell injury by activated oxigen species. Environ Health Perspect 102 (Suppl 10):17-24.
7. Beck M.A., et al. (1998) Dietary oxidative stress and the potentiation of viral infections. Ann Rev Nutr 18:93-116.
8. Henderson B.E., et al. (2000) Hormonal carcinogenesis. Carcinogenesis, 21:427-433.
9. Donaldson, P.T. (1996) Immunogenetics in liver disease. Baillere’s Clinical Gastroenterology, 10:533-545.
10. Yu M-W, et al.. Cytochrome p4502E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 109: 1266-1273.
11. Agundez J.A.G., et al. (1995). CYP2D6 genes and risk of liver cancer. Lancet 345: 380-381.
12. Grove, J., et al. (2000) Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut, 46:540-545.
13. Powell E.E, et al. (2000) Host genetic factors influence disease progression in chronic hepatitis C. Hepatlogy, 31:828-833.
14. Yu, M-W, et al. (2000) Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. JNCI, 92:2023-2028.
15. Asti M, et al. (1999) Human leukocyte antigen class II and III alleleles and severity of hepatitis C virus-related chronic liver disease. Hepatology, 29:1272-1279.
16. McGlynn KA, et al. (1994) Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci USA, 92:2384-2387.
17. Smith BC, et al. (1998) Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology, 27:1695-1699.
18. Chien-Jen C., et al. (1996) Chronic Hepatitis B Carriers With Null Genotipes of Glutathione S-Transferase M1 and T1 Polymorphisms Who Are Exposed to Aflatoxin Are at Increased Risk of Hepatocellular Carcinoma. Am. J. Hum. Genet., 59: 128-134.

WP1-4:
1.De Falco S, et al. J Biol Chem 2001;276:36613-23.
2.Pontisso P, et al. Native hepatitis B virus particles interact with the HBV-binding protein in transfected cells. Antiviral Therapy 2000;5(Suppl.1):39.
3.Rubin H. Serine protease inhibitors (SERPINS): where mechanism meets medicine. Nature Med. 1996;2:632-633.
4.Suminami Y, et al. Biological role of SCC antigen. Tumor Biol 1998;19:488-493.
5.Kato H, et al. SCC antigen and its clinical applications. In Kato H, d Bruijn HWA, Ebert E,et al (eds): SCC Antigen in the management of squamous cell carcinoma. Amsterdam, Excerpta Medica 1987; pp 1-15.
6.Uemura Y, et al. Circulating serpin tumor markers SCCA1 and SCCA2 are not actively secreted but reside in the cytosol of squamous carcinoma cells. Int J Cancer 2000;89:368-377.
7.Pontisso P, et al. High expression of the serine protease inhibitor HBV-binding protein (HBV-BP) in human hepatocarcinoma. In “7th European Meeting on Hepatocarcinogenesis”, Sardinia 2001 (Abstract)
8.Ruvoletto MG, et al. Upregulation of the HBV binding protein (HBV-BP) by the preS1 (21-47) sequence. Antiviral Therapy 2000; 5 (suppl 1):8.30.

Parole Chiave

epatite cronica; cirrosi; epatocarcinoma; HBV; HCV; modelli animali